<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01587235</url>
  </required_header>
  <id_info>
    <org_study_id>0653A-406</org_study_id>
    <nct_id>NCT01587235</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Vytorin Versus Standard Treatment of Other Statins in Moderate, Moderately High and High Risk Participants (MK-0653A-406)</brief_title>
  <acronym>VYCTORY</acronym>
  <official_title>A Multicenter, Open-label, 6 Week Study to Evaluate the Efficacy and Safety of Algorithm Based Intensive Treatment With Vytorin Versus Standard Treatment of Other Statins in Moderate, Moderately High and High Risk Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate and compare the effectiveness of MK-0653 (Vytorin) to current
      standard treatment with other statins for the treatment of dyslipidemia in moderate,
      moderately-high and high-risk participants.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">May 2014</completion_date>
  <primary_completion_date type="Anticipated">May 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants who Achieve Low-density Lipoprotein Cholesterol (LDL-C) goal (High-risk &lt;100 mg/dL; Moderate-high and High risk &lt;130 mg/dL)</measure>
    <time_frame>Week 6</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in LDL-C level From Baseline</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of High-risk Participants who Achieve an LDL-C &lt; 70 mg/dL</measure>
    <time_frame>Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum LDL From Baseline</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Total Cholesterol From Baseline</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in High-density lipoprotein (HDL) From Baseline</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Triglycerides (TG) From Baseline</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Non-HDL From Baseline</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LDL-C/HDL-C Ratio From Baseline</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Apolipoprotein B (ApoB) From Baseline</measure>
    <time_frame>Baseline and Week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants who Achieve non-HDL-C goal (High-risk &lt;100 mg/dL; Moderate-high and High risk &lt;160 mg/dL))</measure>
    <time_frame>Week 6</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Vytorin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Other Statin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe/simvastatin</intervention_name>
    <description>Algorithm based treatment using 10/10mg, 10/20mg and 10/40mg ezetimibe/simvastatin combination tablets orally once daily.</description>
    <arm_group_label>Vytorin</arm_group_label>
    <other_name>Vytorin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Other Statin</intervention_name>
    <description>Participants are prescribed a statin (any other than Vytorin) as per routine standard of care</description>
    <arm_group_label>Other Statin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Low-density lipoprotein cholesterol (LDL-C) ≥100 mg/dL

          -  Either treatment naïve (no previous treatment with lipid-lowering medication) or if
             previously treated with lipid-lowering medication, must complete a wash-out 6 weeks
             prior to enrollment

        Exclusion Criteria:

          -  LDL-C level ≥ 190 mg/dL

          -  Hypersensitivity or intolerance to Vytorin, ezetimibe or simvastatin

          -  Taking other lipid lowering agent except statins. (i.e. fenofibrate, niacin,
             ezetimibe, etc)

          -  Pregnant or breastfeeding, or expecting to conceive within the projected duration of
             the study

          -  Currently participating in or has previously participated in a study within 30 days

          -  Congestive heart failure defined by New York Heart Association (NYHA) Class III or IV
             within previous 6 months

          -  Uncontrolled cardiac arrhythmias or recent significant electrocardiogram (ECG) changes

          -  Unstable angina pectoris

          -  Myocardial infarction, coronary artery bypass surgery, or angioplasty within previous
             3 months

          -  Unstable or severe peripheral artery disease within previous 3 months

          -  Uncontrolled hypertension (treated or untreated)

          -  Type 1 or Type 2 diabetes mellitus that is poorly controlled or recently diagnosed
             (within previous 3 months)

          -  Uncontrolled endocrine or metabolic disease known to influence serum lipids or
             lipoproteins

          -  Serious cerebrovascular disorder (ischemic stroke or cerebral hemorrhage) within the
             previous 6 months

          -  Received treatment with systemic corticosteroids, any cyclical hormones

        within previous 8 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2012</study_first_submitted>
  <study_first_submitted_qc>April 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2012</study_first_posted>
  <last_update_submitted>December 29, 2014</last_update_submitted>
  <last_update_submitted_qc>December 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Ezetimibe, Simvastatin Drug Combination</mesh_term>
    <mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

